<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently an increase of the elderly patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> has been pointed out </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> in elderly patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> (95 age 65 or more), and made a comparative study with non-elderly case for the past 5 years </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">Second malignancies</z:e> were observed in 26 cases out of the total of 282 hematological <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (9.2%) </plain></SENT>
<SENT sid="3" pm="."><plain>The percentage of patients with <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> in the elderly group (19/95; 20%) was significantly higher than that of the non-elderly group (7/187; 3.7%) </plain></SENT>
<SENT sid="4" pm="."><plain>Among the <z:hpo ids='HP_0000001'>all</z:hpo> kinds of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, the <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> were mainly observed in cases with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelo-proliferative disorder </plain></SENT>
<SENT sid="5" pm="."><plain>Colon <z:mp ids='MP_0002038'>carcinoma</z:mp>, gastric <z:mp ids='MP_0002038'>carcinoma</z:mp> and <z:mp ids='MP_0008714'>lung carcinoma</z:mp> accounted for nearly half of <z:hpo ids='HP_0000001'>all</z:hpo> the <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>On 11 of the 26 cases with <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e>, the first <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> had been treated with some anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> drug such as <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Development of a <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> was greater in cases in which the first <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> was treated with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> more than in cases in which the first <z:mp ids='MP_0002038'>carcinoma</z:mp> was not treated with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
</text></document>